



IPO Note

Ambey Laboratories Limited

Recommendation: AVOID!

Company Background -

- Ambey Laboratories, incorporated in 1985, manufactures agrochemical products for crop protection. The company has been serving the agrochemical sector for almost four decades.
- The company manufactures and supplies 2,4-D base chemicals.
- The company's manufacturing facility in Behror, Rajasthan, is certified with ISO 9001:2015 by the Quality Research Organization and ISO 14001:2015 by the United Accreditation Foundation.
- As of October 31, 2023, the company employs 220 people in various departments.

Objects of the Issue -

- To meet Working Capital Requirements
- General Corporate Expenses.
- Issue related expenses

Promoters Name -

Archit Gupta, Arpit Gupta, Sarina Gupta and Rishita Gupta.

Rationale for recommendation -

- ✓ The company's management overview is not very satisfactory
- ✓ The company is operating in less margin compared to its peers in the same industry.
- ✓ The company has had Negative Operating Cashflow for period Ended Jan-2024
- ✓ The company has very high concentration of buyers.

IPO Detail	s				
Opening Da	ate	July 04, 2024			
Closing Dat	te	July 08, 2024			
Allotment I	Date	July 0	9, 2024		
Listing Dat	e	July 1	1, 2024		
Stock Exch	ange	NSE S	SME		
Lot Size		2,000	Shares		
Issue Price	Per Share	₹65 to	o ₹68		
Issue Size		44.68 Cr.			
Fresh Issue	9	42.55 Cr.			
Offer for Sa	le	2.12 Cr.			
Application	Amt	₹ 1,36,000 (2,000			
Аррпсацоі		shares)			
		KPIs			
			(Amt in Lacs)		
KPI's	FY 22	2023	Jan-24		
Revenue	8,460.07	10,482.12	10,031.76		
EBITDA	773.21	769.45	1,067.43		
Net	357.47	456.93	602.73		
Profit					
RoCE	13.86%	12.67%	15.92%		
ROE	18.75%	19.33%	17.57%		

Promoter Share Holding Pattern

26.46

20.42

9.60

Pre-Issue	Post Issue
94.97%	69.90%

Valuation Parameters							
Particulars	Pre-Issue	Post Issue					
EPS	3.86	2.89					
BVPS	41.76	31.29					
P/E	17.64	23.53					
P/BV	1.63	2.17					
Mkt Cap (In Cr)	127.08	169.64					

Lead Managers -

Fast Track Finsec Private Limited

Registrar -

P/E

Link Intime India Private Limited

IPO Note – Ambey Laboratories Limited Recommendation: AVOID



Business Overview -

Originally Incorporated on March 20, 1985, Ambey Laboratories Limited has its registered office in New Delhi. Ambey Laboratories is engaged in the business of manufacturing of agrochemical products for the protecting of crops. The company manufactures and supplies '2,4-D base chemicals' with an emphasis on quality and strict compliance with Environmental, Health, and Safety (EHS) regulations, within the chemical industry.

Manufacturing Facility -

The company's manufacturing Facility located in Behror, Rajasthan, has been certified with ISO 9001:2015 from Quality Research Organization and ISO 14001:2015, certificate of compliance from RoHS Directive (2015/863/EC) European Parliament and commission decision (2005/618/EC).

Products -

Agro-Chemical Products -

- 1. 2,4-D Amine Salt (480 gm. Liter SL)
- 2. 2,4-D Amine Salt (625 gm. Liter SL)
- 3. 2,4-D Amine Salt (720 gm. Liter SL)
- 4. 2,4-D Amine Salt (806 gm. Liter SL)
- 5. 2,4-D Amine Salt (840 gm. Liter SL)
- 6. 2,4-D Amine Salt (866 gm. Liter SL)
- 7. 2,4-D Acid Tech (98% min)
- 8. 2,4-D Ethyl Ester Tech (95% min)
- 9. 2,4-D 2-Ethylhexyl Ester Tech (96% min)
- 10. 2,4-D Sodium Salt (95% min)
- 11. Hexaconazole (5% min)

Revenue Bifurcation as per category is as follows – (Amt in Lakhs)

Home Hygiene Products -

- 1. Black Phenyle
- 2. White Floor Cleaner
- 3. Toilet Cleaner
- 4. Surface & Floor Cleaner
- 5. Power Cleaner
- 6. Glass Cleaner
- 7. Moth Repellent Balls
- 8. Hand Wash
- 9. Bathroom Cleaner
- 10. Hand Sanitizer

Particulars	FY 2	021	FY 20	22	FY 2023		Jan-24	
	Amt	%	Amt %		Amt	%	Amt	%
Agro-Chemical	7,008.55	85.74	7903.16	93.42	9122.31	87.03	9391.49	93.62
Home Hygiene	52.45	0.64	130.67	1.54	340.24	3.25	346.27	3.45
Products								
Others	1,112.93	13.62	426.23	5.04	1019.56	9.73	293.99	2.93
Total	8,173.93	100.00	8460.06	100.00	10482.11	100.00	10031.75	100.00



IPO Note – Ambey Laboratories Limited Recommendation: AVOID



Competition -

The chemical industry is highly competitive. The company faces competition from larger corporates.

There is huge entry barrier in the industry when it comes to manufacturing technical.

The company competes with the competitors on a regional or product line basis.

The company believes that the principal factors affecting competition in the business include relative quality, client relationships, reputation, the abilities of employees, market focus, timely delivery and price of the services and products.

The company's major competitors are Atul Limited, and Meghmani Organics Limited.

Business Strategies -

Continue improving financial performance: through a focus on operational and functional efficiencies. The company is also focused on improving the cost efficiency by optimizing the effective sourcing of raw materials.

Backward integration: The company intends to backwards integrate all Raw materials to the point of basic chemicals which will give the opportunity to increase the bottom line.

Increase in Installed Capacity: The company forecasts it will increase the capacity of current finished goods and in-house manufacturing of the raw material.

Leveraging market expertise, relationships, and leadership position in 2,4-D: This can effectively expand the installed capacity and capitalise on growth opportunities in the market.

Risk Factors -

The Rajasthan State Pollution Control Board has directed the company to deposit the amount to the tune of Rs.1,92,02,400 towards environment compensation.

The company's Top 5 Customers contribute 98.63% revenue in the stub period and 98.88% in the Financial Year 2022-23.

The company, Promoters, Directors and group Companies are involved in certain litigations which if determined against the company, can affect financial conditions of the company.

The company has had negative operating cash flow for period ended Jan-2024.

The company has certain contingent liabilities amounting to Rs. 870.88 lakhs.

Particulars	Ambey Laboratories Limited			Atul Ltd			Meghmani Organics Ltd		
	FY 21	FY 22	FY 23	FY 21	FY 22	FY 23	FY 21	FY 22	FY 23
NP Margin	13%	4%	4%	17%	12%	9%	11%	12%	10%
EBITDA Margin	8%	9%	7%	28%	20%	16%	19%	19%	18%
RoCE	27%	23%	21%	22%	17%	14%	19%	24%	19%
ROE	-	19%	26%	17%	13%	11%	16%	21%	15%
EPS (INR)	21.12	7.08	2.57	221.17	204.23	174.15	7.28	12.11	9.85
P/E	3.22	9.60	26.46	31.74	50.40	39.96	-	8.61	7.89

PEER ANALYSIS



Indian Chemical Industry -

Introduction -

India is the 6th largest producer of chemicals in the world and 3rd in Asia, contributing 7% to India's GDP covering more than 80,000 commercial products and employing more than 2 million people. India's chemical industry is extremely diversified and can be broadly classified into bulk chemicals, specialty chemicals, agrochemical, petrochemicals, polymers, and fertilizers. A network of 200 national laboratories and 1,300 R&D centres provides a strong base to the Indian chemical industry to drive innovations.




• The industry is expected to reach US\$ 304 billion by 2025 at a CAGR of 9.3%, driven by rising demand in the end-user segments for speciality chemicals and petrochemicals segment.

• Chemicals and petrochemicals demand in India is expected to nearly triple and reach US\$ 1 trillion by 2040.

• The petrochemical demand is expected to record a 7.5% CAGR between 2019 and 2023, with the demand for polymers growing at 8%.

• Chemicals and Chemical Products gross bank credit grew by 15.6% in May 2022.

• The agrochemical market in India is expected to register an 8.6% CAGR to reach US\$ 7.4 billion between 2021 and 2026.



Key Growth Driver -

• Rise in Domestic Demand

The growing middle class and increasing urbanisation is driving the demand for personal care, agrochemicals, food, paints & coatings resulting into higher consumption of chemicals per capita.

• Government aims to boost manufacturing share in GDP to 20% by 2025

The government plan includes 2-3 autonomous zones which does not have labor and land laws. \sim 300 companies are actively pursuing production plans in mobiles, electronics, medical devices and textiles.

• Rise in Disinfectant demand post Covid-19

With increasing demand for disinfestation of personal and public places post COVID-19, the chloroalkali, ethanol, personal care, and surfactant industry is expected to record significant growth in near future.

• Foreign Investment

Presence of prominent global players, such as BASF, Dow Chemicals, Bayer and others, 100% FDI in the chemicals sector and stringent laws on anti-dumping to drive the Indian chemical market.

Government Initiatives -

- The government plans to implement production-link incentive system with 10-20% output incentives for the agrochemical sector; to create an end-to-end manufacturing ecosystem through the growth of clusters.
- 100% FDI is allowed in the chemical sector under automatic route with exception to few hazardous chemicals.
- The Indian Government supports the industry in research & development, reduced the basic customs duty on several products and offers support through the 'Make in India' campaign.

Key Management -





Key Management Persons Name -	Sarina Gupta
Age	42
Designation and No. of years of experience	Promoter, and Whole-Time Director, 15 Years of experience
Qualification	Bachelor of Arts (Hons.) in Psychology
Roles and Responsibility	Handling Human Resource Management of the company
Other Directorships	Dhansa Consumers Private Limited

Key Management Persons Name -	Abdul Quadir		
Age	33		
Designation and No. of years of experience	Independent Director, 6 years of experience		
Qualification	Company Secretary		
Roles and Responsibility	Handles Property Laws, Listing Agreement and SEBI Regulation		
	Compliance of the company		
Other Directorships	-		

Key Management Persons Name -	Rishita Gupta		
Age	36		
Designation and No. of years of experience	Promoter, and Non-Executive Director, 11 years of experience		
Qualification	Bachelor of Science Management		
Roles and Responsibility	Handling Administration of the company		
Other Directorships	Aromatic Rasayan Private Limited and Dhansa Consumers Private		
	Limited		

Key Management Persons Name -	Sandeep Bansal	
Age	43	
Designation and No. of years of experience	Non-Executive Director, 15 years of experience	
Qualification	B. Com Degree	
Roles and Responsibility	Handling Business Development and Marketing of the company	
Other Directorships	Aromatic Rasayan Private Limited, SG Reftech Private Limited and	
	Fission Pharmaceuticals Private Limited	

Key Management Persons Name -	Roni Soni
Age	36
Designation and No. of years of experience	Independent Director, 9+ years of experience
Qualification	CS, LLB, B. Com
Roles and Responsibility	-
Other Ventures	Senior Consultant at his own practicing firm.



Amt in Lakhs.

2,641.52

3,009.56

FINANCIAL SNAPSHOT

Statement of Profit and Loss

Total Non-Current assets


Particulars	FY 21	FY 22	FY 23	Jan-24
Revenue from Operations	8,173.94	8,460.07	10,482.12	10,031.76
Other Income	67.60	51.12	261.35	11.93
Total Income	8,241.54	8,511.19	10,743.47	10,043.69
<u>Expenses</u>				
Cost of Material Consumed	6,447.80	6,991.03	9,294.15	8,871.50
Change in Inventories	187.55	-101.34	-302.97	-518.83
Employee Benefit Expenses	191.02	195.03	241.50	170.27
Finance Cost	409.53	305.11	183.73	158.10
Depreciation and Amortisation	322.22	297.03	296.26	283.29
Other expenses	374.57	341.26	408.06	241.39
Total Expenses	7,932.69	8,028.12	10,120.73	9,205.72
EBITDA	615.82	773.21	769.45	1,067.43
EBITDA Margin	7.53%	9.14%	7.34%	10.64%
Profit/(Loss) before exceptional items and tax	308.85	483.07	622.74	837.97
Exceptional Items	-	-	0.83	-
Profit/(Loss) before tax	308.85	483.07	621.91	837.97
<u>Tax Expense</u>				
Current tax	51.55	80.63	103.81	139.87
Deferred Tax Expenses/(credit)	-724.83	125.60	164.98	235.24
MAT credit entitlement	-51.55	-80.63	-103.81	-139.87
Total Tax	-724.83	125.60	164.98	235.24
Profit/(Loss) for the year	1,033.68	357.47	456.93	602.73
Net Profit Margin	12.54%	4.20%	4.25%	6.00%

Statement of Assets and Liabilities Amt in Lakhs. Particulars FY 21 FY 22 FY 23 Jan-24 **EQUITY AND LIABILITIES** 1. Shareholders' funds Share Capital 489.35 1,774.94 1,774.94 1,868.88 **Reserves and surplus** -1,275.74 131.73 588.66 1,562.46 **Total Equity** -786.39 1,906.67 2,363.60 3,431.34 2. Non-current liabilities Long-term borrowings 2,959.74 1,430.55 1,273.35 1,394.31 Other Non-Current Liabilities 48.97 46.93 46.93 46.93 Long Term Provisions 47.11 50.60 50.47 53.66 **Total Non-current liabilities** 3,055.82 1,528.08 1,370.75 1,494.90 3. Current liabilities Short -term borrowings 333.24 374.31 91.87 611.13 **Trade Payables** 1,619.44 1,487.48 1,623.04 2,606.26 Other Current Liabilities 135.44 110.44 98.16 195.01 Short-term provisions 104.25 185.96 214.43 282.20 **Total Current liabilities** 2,192.37 2,158.19 2,027.50 3,694.60 **Total Liabilities** 5,248.19 3,686.27 3,398.25 5,189.50 **Total Equity and Liabilities** 4,461.80 5,592.94 5,761.85 8,620.84 ASSETS 1. Non-current assets Property, Plant and Equipment 2,411.08 2,170.58 1,457.38 2,421.84 **Intangible Assets** 127.47 97.73 99.88 75.88 Work-In-Progress 95.12 133.58 Deferred Tax Assets (Net) 722.59 596.99 432.01 196.77 Long Term Loans and Advances 56.15 55.12 55.83 64.71

2,458.71

3,160.92

IPO Note – Ambey Laboratories Limited





Amt in lakhs.

Particulars	FY 21	FY 22	FY 23	Jan-24
2. Current assets				,
Current Investments	-	-	60.44	78.12
Inventories	873.23	1,075.09	1,712.03	2,210.57
Trade Receivables	696.68	852.44	356.51	2,844.50
Cash & Cash equivalents	51.10	28.90	41.09	23.22
Short term loans and advances	237.08	275.02	284.44	329.23
Other Current Assets	145.00	200.57	297.78	493.68
Total Current assets	2,003.09	2,432.02	2,752.29	5,979.32
Total Assets	4,461.80	5,592.94	5,761.85	8,620.84

Cash Flow Statement

Particulars	FY 21	FY 22	FY 23	Jan-24
Net Cash Flow from Operating Activities	274.31	560.73	944.11	-823.46
Net Cash Flow from Investing Activities	-116.71	-75.30	-308.55	-141.55
Net Cash Flow from Financing Activities	-149.02	-507.64	-623.37	947.13

Key Ratios

<u>Per Share Data</u>	FY 22	FY 23	Jan-24*	Valuation Ratios (x)	FY 22	FY 23	
Diluted EPS	7.08	2.57	5.52	EV/EBITDA	4.76	4.79	
BV per share	32.97	35.42	43.42	Market Cap / Sales	2.01	1.62	
Operating Ratios				P/E	9.60	26.46	
EBITDA Margins	9.14%	7.34%	10.64%	Price to Book Value	2.06	1.92	
PAT Margins	4.20%	4.25%	6.00%				
Inventory days	46.38	59.61	60.82	Solvency Ratios			
Debtor days	36.78	12.41	78.26	Debt / Equity	0.95	0.58	
Creditor days	87.02	69.24	87.03	Current Ratio	1.13	1.36	
Return Ratios				Quick Ratio	0.73	1.18	
RoCE	13.86%	12.67%	13.88%	Asset Turnover	1.51	1.82	
RoE	18.75%	19.33%	9.24%	Interest Coverage Ratio	1.56	2.58	

*Jan-24 data are annualized



LEAD MANAGER TRACK RECORD -

The lead manager to the issue is Fast Track Finsec Private Limited. A table has been set below highlighting the details of the IPO of the last companies handled by the Lead Manager in recent times –

Fast Track Finsec Private Limited -

Sr.	Company Name	Issue Size	Issue	Listing Date	CMP*
No.		in Cr.	Price/Share		(INR)
			(In INR)		
1.	Enser Communications Limited	16.17	70.00	March 22, 2024	172.85
2.	Sungarner Energies Limited	5.31	83.00	Aug 31, 2023	389.50
3.	Pearl Green Clubs and Resorts Limited	11.72	186.00	July 07, 2022	155.95
4.	Globesecure Technologies Limited	10.13	29.00	June 02, 2022	44.20
5.	Jeena Sikho Lifecare Limited	55.50	150.00	April 19, 2022	1,077.35
6.	SBL Infratech Limited	2.37	111.00	Sep 28, 2021	36.10
7.	Trekkingtoes.com Limited	4.54	105.00	Aug 28, 2020	29.2
8.	Ascom Leasing & Investments Limited	6.32	30.00	Dec 06, 2019	110.60
9.	Goblin India Limited	15.20	52.00	Oct 15, 2019	42.29
10.	Kranti Industries Limited	8.58	37.00	Feb 28, 2019	68.44

The company has handled 6 mandates in the past three years.

*CMP for the above-mentioned companies is taken as of 2nd July 2024.

As per the offer document, from the above-mentioned mandates 2 have opened at discount and the remaining have opened at premium on the listing day.

IPO Note – Ambey Laboratories Limited Recommendation: AVOID Recommendation -



The company has been in the industry since 1985 and has vast experience in the industry. The management overview of the company is not very satisfactory.

The P/E on a post-IPO and annualised basis is around 17.64 times which makes it fairly priced by looking at the performance of the company and sector. The Sector P/E is 50.4 times.

The company has seen a dip in its bottom line for FY 2022. The company operates in a very competitive segment. The companies in the same industry are operating with better margins. The company has had negative operating cash flow for the period ended Jan-2024. The company has a very high concentration of buyers which is not a very satisfactory thing for the company. Thus, we recommend **AVOID** applying to this company and would not be missing out on the investment.



Disclaimer

We are not registered research analysts with SEBI and are not subject to the regulations governing research analysts. This research report is for educational purposes only and should not be construed as investment advice. The information contained in this report is based on publicly available information and is believed to be reliable, but no representation or warranty, express or implied, is made as to its accuracy or completeness. Also, some of the employees of our organization may have or may in the future hold investments in the company that is the subject of this research report. This may create a conflict of interest, and you should be aware of this when considering the information contained in this report. You should consult with your financial advisor before making any investment decisions.

OUR WEBSITE:

www.tiareconsilium.com

CONNECT WITH US ON :

